BP1212 is a novel anti-tumor therapeutic antibody developed by BrightPath that exerts superior antitumor immunity by simultaneously suppressing multiple immunosuppressive mechanisms.
BP1212 preferentially targets TIM-3+ CD39+ T cells and dendritic cells and inhibits CD39-induced suppression and TIM-3-mediated dysfunction of immune cells.
The ectoenzyme CD39 catalyzes the conversion of eATP to AMP, resulting in an increase in extracellular adenosine, which has an anti-inflammatory effect, thereby shifting the tumor microenvironment (TME) into an immunosuppressive state. In addition, dying tumor cells release eATP to the TME, which further promotes tumor immunity. However, the degradation of eATP by CD39 is known to abolish the promotion of antitumor immunity.
TIM-3 is a cell surface protein that is expressed on activated T cells and dendritic cells promoting T cell exhaustion and suppression in the TME. Furthermore, TIM-3 acts as an immune checkpoint that regulates innate and adaptive immune responses by acting as a “brake” on the immune system. TIM-3 is also strongly expressed on tumor-infiltrating T cells and negatively regulates antitumor immunity by modulating the activity of the inflammasome.
CD39 and TIM-3 belong to a group of molecules simultaneously expressed on activated T cells and antigen-presenting cells responsible for killing tumor cells and are suppressing anti-tumor immunity.
Thus, tumor cells utilize multiple mechanisms to either evade immune cell detection or inhibit the anti-tumor immune response, diminishing the tumor-killing potential of host immune system. BP1212 blocks these immunosuppressive mechanisms and exerts a strong antitumor effect.